A Rollover Protocol for Subjects Previously Treated With AGS-003
A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects With Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006
Sponsor: Argos Therapeutics
Terminated
Lack of efficacy
Other terminated trials from Argos Therapeutics
- Advanced Renal Cell Carcinoma · Phase PHASE3 · Apr 2018
- Genitourinary Cancer (Bladder, Prostate or Testicular) · Phase NA · Sep 2017
More terminations from Argos Therapeutics
Other Renal Cell Carcinoma trials with similar outcome
A PHASE2 clinical study on Renal Cell Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Argos Therapeutics and has accumulated 7 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jul 2018 — Jan 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Argos Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .